A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer

被引：0
|
作者：
De Tursi, M. [1 ]
Carella, C. [1 ]
Ricevuto, E. [1 ]
Gennari, A. [2 ]
Orlandini, C. [2 ]
Frassoldati, A. [3 ]
Conte, P. F. [3 ]
Iacobelli, S. [1 ]
机构：
[1] Univ G DAnnunzio, Chieti, Italy
[2] Univ Aquila, I-67100 Laquila, Italy
[3] Univ Modena, I-41100 Modena, Italy
来源：
BREAST | 2007年 / 16卷
关键词：
D O I：
10.1016/S0960-9776(07)70161-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [1] A multicenter phase II study of epirubicin with low-dose trastuzumab as a first line treatment in Her-2 overexpressing metastatic breast cancer: preliminary results
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 165 - 165
  • [2] A multicenter Phase II study of Epirubicin (E) with low-dose Herceptin (LD-H) as a first line treatment in HER-2 overexpressing metastatic breast cancer (MBC): Preliminary results
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Marchetti, P.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P.
    Iacobelli, S.
    EJC SUPPLEMENTS, 2005, 3 (02): : 116 - 116
  • [3] A multicenter phase II study of epirubicin (E) with low-dose herceptin (LD-H) as a first-line treatment in HER2 overexpressing metastatic breast cancer (MBC)
    De Tursi, M.
    Carella, C.
    Ricevuto, E.
    Gennari, A.
    Orlandini, C.
    Frassoldati, A.
    Conte, P. F.
    Iacobelli, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    M. Venturini
    C. Bighin
    S. Monfardini
    F. Cappuzzo
    N. Olmeo
    A. Durando
    F. Puglisi
    O. Nicoletto
    A. Lambiase
    L. Del Mastro
    Breast Cancer Research and Treatment, 2006, 95 : 45 - 53
  • [5] Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer
    Venturini, M
    Bighin, C
    Monfardini, S
    Cappuzzo, F
    Olmeo, N
    Durando, A
    Puglisi, F
    Nicoletto, O
    Lambiase, A
    Del Mastro, L
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (01) : 45 - 53
  • [6] Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial
    Chia, Stephen
    Clemons, Mark
    Martin, Lee-Ann
    Rodgers, Angela
    Gelmon, Karen
    Pond, Gregory R.
    Panasci, Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2773 - 2778
  • [7] Multinational phase II study of navelbine (N) and herceptin (H) as first-line therapy for HER2-overexpressing metastatic breast cancer (HER2+MBC).
    Chan, A
    Untch, M
    Petruzelka, L
    Martin, M
    Porta, VG
    Gil, M
    Kellokumpu-Lehtinen, P
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S112 - S112
  • [8] Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan
    Tokudome, Nahomi
    Ito, Yoshinori
    Hatake, Kiyohiko
    Toi, Masakazu
    Sano, Muneaki
    Iwata, Hiroji
    Sato, Yasuyuki
    Saeki, Toshiaki
    Aogi, Kenjiro
    Takashima, Shigemitsu
    ANTI-CANCER DRUGS, 2008, 19 (07) : 753 - 759
  • [9] Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Gennari, Alessandra
    De Tursi, Michele
    Carella, Consiglia
    Ricevuto, Enrico
    Orlandini, Cinzia
    Frassoldati, Antonio
    Conte, Pierfranco
    Bruzzi, Paolo
    Iacobelli, Stefano
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 115 (01) : 131 - 136
  • [10] Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer
    Alessandra Gennari
    Michele De Tursi
    Consiglia Carella
    Enrico Ricevuto
    Cinzia Orlandini
    Antonio Frassoldati
    Pierfranco Conte
    Paolo Bruzzi
    Stefano Iacobelli
    Breast Cancer Research and Treatment, 2009, 115 : 131 - 136
12345